Sangamo BioSciences Inc. reported promising early data from its Phase II trial of zinc finger protein therapeutic SB-509, showing that it improved muscle function in amyotrophic lateral sclerosis patients, though it remains to be seen whether those results will translate into a win for the company down the road. (BioWorld Today) Read More
